



8 November 2021

Medicine Supply Alert Notice

Latanoprost 50microgram/ml / timolol 5mg/ml (Fixapost[®]) 0.2ml unit dose preservative free eye drops

Priority: Level 2*

Valid until: Mid November 2021

Issue

1. Fixapost[®] eye drops are out of stock until mid-November 2021.
2. Latanoprost (Monopost[®]) 50microgram/ml 0.2ml unit dose preservative free eye drops remain available.
3. Timolol (Eysano[®]) 5mg/ml and 2.5mg/ml eye drops preservative free and timolol (Tiopex[®]) 1mg/g gel eye drops 0.4g unit dose preservative free remain available.
4. Other preservative-free combination eye drops also remain available.

Advice and Actions

5. For patients with insufficient supplies, clinicians should consider the following options during the affected period, taking into account patient preferences:
 - prescribing Monopost[®] with Eysano[®] 5mg/ml eye drops which contain the same constituents as Fixapost[®];
 - prescribing Monopost[®] with Eysano[®] 2.5mg/ml eye drops or Tiopex[®] gel eye drops if Eysano[®] 5mg/ml eye drops are not appropriate or unavailable;
 - prescribing an alternative preservative-free combination eye drop if administration of multiple products is an issue;
 - reassuring patients that any changes to their eye drops will be short-term and for the duration of the supply issue only; and
 - deferring initiating any new patients on Fixapost[®] eye drops until the supply issue is resolved

Additional Information

Alternative preservative free eye preparations

Generic name (brand name)	Strength	Stock status
Latanoprost (Monopost [®]) 0.2ml unit dose eye drops	50microgram/ml	In stock
Timolol (Eysano [®]) eye drops	5mg/ml	In stock
Timolol (Eysano [®]) eye drops	2.5mg/ml*	In stock
Timolol (Tiopex [®]) gel eye drops 0.4g unit dose	1mg/g*	In stock
Bimatoprost & timolol (Ganfort [®]) eye drops, solution, in single-dose container	0.3 mg/ml + 5 mg/ml	In stock
Tafluprost & timolol (Taptiqom [®]) eye drops, solution in single-dose container	15 micrograms/ml + 5 mg/ml	In stock

*Speciality advice is that, for the majority of patients, a short-term change in the strength of timolol drops is unlikely to have an adverse clinical effect.

6. Please refer to the following links for further information on alternative preparations:

- [Fixapost[®] SPC](#)
- [Eysano[®] SPC](#)
- [Ganfort[®] SPC](#)
- [Taptiqom[®] SPC](#)
- [Tiopex[®] SPC](#)
- [Monopost[®] SPC](#)
- [Glaucoma and ocular hypertension BNF](#)

Enquiries

7. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).